Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 2.

Journal Article

Barlesi, F., Wolf, J., Ahn, M-J., Doebele, R. C., Paz-Ares, L., Rolfo, C., Siena, S., Seto, T., Ohe, Y., Ou, S. H. I., Krebs, M. G., Kapre, A., Piault-Louis, E., McCallum, S., Osborne, S., Aziez, A. and Drilon, A. (2020). Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study. Ann. Oncol., 31. S. S1391 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Dziadziuszko, R., Siena, S., Tan, D. S. W., Cho, B. C., Ahn, M-J., Goto, K., Garrido-Lopez, P., Farago, A. F., Loong, H. H. F., Tosi, D., John, T., Wolf, J., Chiu, C-H., Liu, S. V., Patel, M. R., Drilon, A., Pitcher, B., Simmons, B. and Doebele, R. C. (2020). Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline. Ann. Oncol., 31. S. S833 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

This list was generated on Mon Jun 14 03:23:49 2021 CEST.